Clinical Trial Update: Osimertinib With Chemotherapy as First-line Therapy for EGFR Mutation-positive NSCLC

View source ↗

Summary

Update on a clinical trial evaluating the combination of osimertinib with chemotherapy as first-line therapy for EGFR mutation-positive non-small cell lung canc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Osimertinib (osimertinib)

Snippet

Sponsor: AstraZeneca | Conditions: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms | Status: ACTIVE_NOT_RECRUITING